WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 $
arrow_upward
+0,48%(+0,060) 1D
16 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WXXWY...
Open
12,29 $
High
12,56 $
Low
12,20 $
Mkt. cap
198,43 млрд
Avg. vol.
61,89 мың
Volume
110,85 м.
52-wk high
14,80 $
52-wk low
7,30 $
Beta
0,01
Shares outstanding
2,06 млрд
No. of employees
15 мың
Open
12,29 $
High
12,56 $
Low
12,20 $
Mkt. cap
198,43 млрд
Avg. vol.
61,89 мың
Volume
110,85 м.
52-wk high
14,80 $
52-wk low
7,30 $
Beta
0,01
Shares outstanding
2,06 млрд
No. of employees
15 мың
News stories
From web sources and news partners
The Fintech Times
·
40 минут бұрын
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Yahoo Finance
·
1 сағат бұрын
Anthropic IPO Buzz Has Investors Watching Nasdaq Stock And ECM Fee Winners
BeInCrypto
·
1 сағат бұрын
Black Monday Fears Fade as Nasdaq Futures Rally After Friday Selloff
Bloomberg.com
·
4 сағат бұрын
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics Cayman ADR